Sanguine Corp. (SGUI) is “One to Watch”
Founded in 1974, Sanguine Corp. is a company focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices. The Company's lead product is PHER-02. This intravenous perfluorocarbon emulsion is highly efficient at dissolving and delivering oxygen to tissues. These properties make PHER-02 an ideal product for the treatment of an array of medical conditions with high morbidity and/or mortality directly resulting from a lack of oxygen at the cellular level. Sanguine's shares trade on the OTC Bulletin Board and the Company has their corporate headquarters in Roswell, Georgia. PHER-O2 is a reformulated version of Fluosol-DA.…